We remain committed to help solve the dual epidemics of unresolved pain and prescription opioid abuse that is affecting more people and consuming more financial resources in the United States and Canada than cancer, diabetes, and heart disease combined.
(PRWEB) April 05, 2016
Proove Biosciences, Inc., the commercial and research leader in personalized pain medicine, is pleased to announce its strategic partnership and support of the Canadian Institutes for Health Research (CIHR) initiative. On March 31, 2016, the Honorable Jane Philpott, the Canadian Minister of Health, announced the government’s $65 million investment in the Strategy for Patient Outcomes Research (SPOR) to address chronic conditions, including chronic pain, gastrointestinal disorders, chronic kidney disease, child disability, and diabetes. As a strategic partner and sponsor of the Chronic Pain Network, Proove Biosciences is positioned to play an important role in helping the research move from the lab into the clinical setting. The approach is aimed at helping patients manage pain more effectively and avoid the early path to prescription opioid abuse.
During the announcement, the Honorable Jane Philpott shared that “SPOR provides a valuable platform for the federal government to work with partners across the country to improve health care for Canadians. We are pleased to support these networks whose work will lead to better health and a better quality of life for Canadians and help reduce the burden of chronic disease on our health care system.” The Canadian Institute of Health Research President Dr. Alain Beaudet explained that “these networks will produce innovations that improve the health of Canadians and position Canada as a global leader in research on these chronic disease. We thank all the partners supporting these networks for their strong commitment and generous contributions.”
As the genetic and diagnostic partner for the SPOR network in Chronic Pain, Proove Biosciences is able to leverage its leadership in research and clinical testing in the United States.Brian Meshkin, CEO at Proove Biosciences, attended Minister Philpott’s reception to support the announcement at McMaster University. As a pioneer in genetic testing, Proove Biosciences uses technology that can further support the efforts of the Canadian government. “Chronic pain knows no border,” said Meshkin. “We are encouraged by the vision of the Canadian government to make this significant investment to address chronic conditions that affect so many lives. In an effort to do our part, we are able to leverage our proprietary technology platform to evaluate genetic variations and related factors to improve the decisions involved in avoiding, diagnosing, and treating chronic pain and its related conditions.”
Proove Biosciences continues to align itself with the leading researchers involved in pain and genetics across the globe. As Meshkin explains, “Proove is proud to support the vision of Dr. David Buckley and all of the research collaborators across Canada. It was humbling to gather together as a team to launch this effort. I am confident that this initiative will not only help Canadians, but also patients, physicians, and health care systems in the United States and across the globe.”
Led by Dr. David Buckley, a professor and Chair of the Department of Anesthesia at McMaster University Medical Center, the Chronic Pain Network is designed to direct research efforts, train clinicians, and facilitate access to better care. In addition, the network is focused on accelerating the transition from research to care. “We are pleased to see an added focus on enhancing individual care for patients in pain by involving genetics,” said Meshkin. “We remain committed to help solve the dual epidemics of unresolved pain and prescription opioid abuse that is affecting more people and consuming more financial resources in the United States and Canada than cancer, diabetes, and heart disease combined.”
About Proove Biosciences
Our mission is to change the future of medicine. Proove represents the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could have ever prescribed medications without knowing how a patient would respond. Physicians use Proove Biosciences testing to improve outcomes—both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).